Tech Company Financing Transactions
Oncomatryx Funding Round
Oncomatryx, based in Derio. Bizkaia, scored $26 million from CDTI.
Transaction Overview
Company Name
Announced On
1/27/2025
Transaction Type
Venture Equity
Amount
$26,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D sector.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Parque Tecnológico de Bizkaia 801B -- 2P
Derio. Bizkaia, 48160
Spain
Derio. Bizkaia, 48160
Spain
Phone
Website
Email Address
Overview
Our mission is to revolutionize Oncology, through targeted intervention in the tumor microenvironment with next-generation drugs. In our constant pursuit of patient improvement, Oncomatryx vision is to turn immune-cold into immune-hot tumors, prolong and improve the quality of life for patients suffering from metastatic solid tumors and cure cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Laureano Simón
Chief Marketing Officer
Ignacio García
Chief Operating Officer
Manuel Sanz
Chief Scientific Officer
Myriam Fabre
VP - Bus. Development
David Raksin
VP - Product Management
Pedro Esnaola
Browse more venture capital transactions:
Prev: 1/27/2025: Satisfi Labs venture capital transaction
Next: 1/27/2025: FlexGen Power Systems venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on tech company VC transactions. VC transactions on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs